Marks Shearman News Today

Editas Medicine (NASDAQ:EDIT – Get Rating) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Friday. A number of other brokerages also recently issued reports on EDIT. SVB Leerink lifted their price target on Editas Medicine from $6.00 to $7.00 and gave the stock a […]

Editas Medicine (NASDAQ:EDIT – Get Rating) released its earnings results on Friday. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.08, Briefing.com reports. The firm had revenue of $9.90 million for the quarter, compared to analyst estimates of $3.29 million. Editas Medicine had a negative […]

Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) has been given a consensus recommendation of “Hold” by the sixteen brokerages that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and four have issued a buy recommendation on the company. The […]

Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) shares shot up 8.4% during trading on Monday . The stock traded as high as $8.32 and last traded at $8.23. 443,238 shares were traded during trading, a decline of 75% from the average session volume of 1,793,685 shares. The stock had previously closed at $7.59. Wall Street […]

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) have been given an average rating of “Hold” by the sixteen ratings firms that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to […]

Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) fell 4.3% during trading on Wednesday . The company traded as low as $7.70 and last traded at $7.70. 317,125 shares traded hands during trading, a decline of 82% from the average session volume of 1,730,446 shares. The stock had previously closed at $8.05. Analyst Upgrades and Downgrades […]

Pictet Asset Management SA lifted its stake in Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 37.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 182,186 shares of the company’s stock after purchasing an additional 49,782 shares during the quarter. Pictet Asset Management […]

Pictet Asset Management SA raised its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 37.6% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 182,186 shares of the company’s stock after purchasing an additional 49,782 shares during the period. Pictet Asset Management SA […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.